160 related articles for article (PubMed ID: 29935395)
1. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer.
Stewart LM; Spilsbury K; Jordan S; Stewart C; Holman CDJ; Powell A; Reekie J; Cohen P
Cancer Epidemiol; 2018 Aug; 55():110-116. PubMed ID: 29935395
[TBL] [Abstract][Full Text] [Related]
2. Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
Stewart LM; Stewart CJR; Spilsbury K; Cohen PA; Jordan S
Gynecol Oncol; 2020 Mar; 156(3):611-615. PubMed ID: 31983516
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study.
Rasmussen CB; Jensen A; Albieri V; Andersen KK; Kjaer SK
Gynecol Oncol; 2016 Nov; 143(2):346-351. PubMed ID: 27549433
[TBL] [Abstract][Full Text] [Related]
4. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
[TBL] [Abstract][Full Text] [Related]
5. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.
Hannibal CG; Vang R; Junge J; Kjaerbye-Thygesen A; Kurman RJ; Kjaer SK
Gynecol Oncol; 2012 Jun; 125(3):655-60. PubMed ID: 22370600
[TBL] [Abstract][Full Text] [Related]
6. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
7. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
8. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
9. Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies.
Rasmussen CB; Kjaer SK; Albieri V; Bandera EV; Doherty JA; Høgdall E; Webb PM; Jordan SJ; Rossing MA; Wicklund KG; Goodman MT; Modugno F; Moysich KB; Ness RB; Edwards RP; Schildkraut JM; Berchuck A; Olson SH; Kiemeney LA; Massuger LF; Narod SA; Phelan CM; Anton-Culver H; Ziogas A; Wu AH; Pearce CL; Risch HA; Jensen A;
Am J Epidemiol; 2017 Jan; 185(1):8-20. PubMed ID: 27941069
[TBL] [Abstract][Full Text] [Related]
10. Pelvic inflammatory disease and the risk of epithelial ovarian cancer.
Risch HA; Howe GR
Cancer Epidemiol Biomarkers Prev; 1995; 4(5):447-51. PubMed ID: 7549798
[TBL] [Abstract][Full Text] [Related]
11. Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study.
Shen CC; Hu LY; Yang AC; Chiang YY; Hung JH; Tsai SJ
BMC Cancer; 2016 Nov; 16(1):839. PubMed ID: 27809870
[TBL] [Abstract][Full Text] [Related]
12. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
13. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk.
Stewart LM; Holman CD; Aboagye-Sarfo P; Finn JC; Preen DB; Hart R
Gynecol Oncol; 2013 Feb; 128(2):260-4. PubMed ID: 23116937
[TBL] [Abstract][Full Text] [Related]
14. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study.
Huusom LD; Frederiksen K; Høgdall EV; Glud E; Christensen L; Høgdall CK; Blaakaer J; Kjaer SK
Cancer Causes Control; 2006 Aug; 17(6):821-9. PubMed ID: 16783610
[TBL] [Abstract][Full Text] [Related]
15. Is Pelvic Inflammatory Disease a Risk Factor for Ovarian Cancer?
Rasmussen CB; Jensen A; Albieri V; Andersen KK; Kjaer SK
Cancer Epidemiol Biomarkers Prev; 2017 Jan; 26(1):104-109. PubMed ID: 27672055
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for ovarian cancers with and without microsatellite instability.
Segev Y; Pal T; Rosen B; McLaughlin JR; Sellers TA; Risch HA; Zhang S; Sun P; Narod SA; Schildkraut J
Int J Gynecol Cancer; 2014 May; 24(4):664-9. PubMed ID: 24755492
[TBL] [Abstract][Full Text] [Related]
17. Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario.
McGee J; Panabaker K; Leonard S; Ainsworth P; Elit L; Shariff SZ
Int J Gynecol Cancer; 2017 Mar; 27(3):437-443. PubMed ID: 28072594
[TBL] [Abstract][Full Text] [Related]
18. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
19. [Endometriosis as a risk factor for ovarian cancer].
Vargas-Hernández VM
Cir Cir; 2013; 81(2):163-8. PubMed ID: 23522320
[TBL] [Abstract][Full Text] [Related]
20. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
